Background and Purpose. This project examined the in vitro??γH2AX response in lymphocytes of prostate cancer patients who had a radiosensitive response after receiving radiotherapy. The goal of this project was to determine whether the γH2AX response, as measured by flow cytometry, could be used as a marker of individual patient radiosensitivity. Materials and Methods. Patients were selected from a randomized clinical trial evaluating the optimal timing of Dose Escalated Radiation and short-course Androgen Deprivation Therapy. Of 438 patients, 3% developed Grade 3 late radiation proctitis and were considered to be radiosensitive. Blood was drawn from 10 of these patients along with 20 matched samples from patients with Grade 0 proctitis. Dose response curves up to 10?Gy along with time response curves after 2?Gy (0–24?h) were generated for each sample. The γH2AX response in lymphocytes and lymphocyte subsets was analyzed by flow cytometry. Results. There were no significant differences between the radiosensitive and control samples for either the dose course or the time course. Conclusions. Although γH2AX response has previously been demonstrated to be an indicator of individual patient radiosensitivity, flow cytometry lacks the sensitivity necessary to distinguish any differences between samples from control and radiosensitive patients. 1. Introduction The severity of late normal tissue toxicity is a limiting factor during the administration of radiotherapy [1]. It has become clear that interpatient variability in the incidence of late normal tissue toxicity could be partially due to individual patient sensitivity to radiation [2] and the prediction of a patient’s radiosensitivity would facilitate improved patient treatment [3]. The induction and repair of chromosomal damage in irradiated lymphocytes are thought to be promising predictors of individual patient sensitivity to ionizing radiation [4]. Since DNA double-strand breaks (DSBs) are considered to be the critical lesion for DNA damage, the lack of repair, or misrepair, can have severe repercussions. As such, it is important to be able to quantitate the induction and disappearance of DSBs. Rogakou et al. in 1999 [5] showed that H2AX (an electrophoretic isoform of the histone H2A) is phosphorylated (γH2AX) at the sites of DSBs, and Sedelnikova et al. in 2003 [4] demonstrated that γH2AX foci corresponded one to one with DSBs. These results mean that the number of DSBs induced can be measured by counting the number of γH2AX foci [4]. Furthermore, by staining γH2AX with a fluorochrome-labelled
References
[1]
B. Emami, J. Lyman, A. Brown et al., “Tolerance of normal tissue to therapeutic irradiation,” International Journal of Radiation Oncology, Biology, Physics, vol. 21, no. 1, pp. 109–122, 1991.
[2]
S. M. Bentzen and J. Overgaard, “Patient-to-patient variability in the expression of radiation-induced normal tissue injury,” Seminars in Radiation Oncology, vol. 4, no. 2, pp. 68–80, 1994.
[3]
L. A. Henriquez-Hernandez, E. Bordon, B. Pinar, M. Lloret, C. Rodriguez-Gallego, and P. C. Lara, “Prediction of normal tissue toxicity as part of the individualized treatment with radiotherapy in oncology patients,” Surgical Oncology, vol. 21, pp. 201–206, 2012.
[4]
O. A. Sedelnikova, D. R. Pilch, C. Redon, and W. M. Bonner, “Histone H2AX in DNA damage and repair,” Cancer Biology and Therapy, vol. 2, no. 3, pp. 233–235, 2003.
[5]
E. P. Rogakou, C. Boon, C. Redon, and W. M. Bonner, “Megabase chromatin domains involved in DNA double-strand breaks in vivo,” Journal of Cell Biology, vol. 146, no. 5, pp. 905–915, 1999.
[6]
P. L. Olive and J. P. Banáth, “Phosphorylation of histone H2AX as a measure of radiosensitivity,” International Journal of Radiation Oncology, Biology, Physics, vol. 58, no. 2, pp. 331–335, 2004.
[7]
C. E. Rübe, A. Fricke, J. Wendorf et al., “Accumulation of DNA double-strand breaks in normal tissues after fractionated irradiation,” International Journal of Radiation Oncology, Biology, Physics, vol. 76, no. 4, pp. 1206–1213, 2010.
[8]
A. Menegakis, A. Yaromina, W. Eicheler et al., “Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by γH2AX staining,” International Journal of Radiation Biology, vol. 85, no. 11, pp. 1032–1041, 2009.
[9]
J. Werbrouck, K. De Ruyck, L. Beels et al., “Prediction of late normal tissue complications in RT treated gynaecological cancer patients: potential of the γ-H2AX foci assay and association with chromosomal radiosensitivity,” Oncology Reports, vol. 23, no. 2, pp. 571–578, 2010.
[10]
M. L. K. Chua, N. Somaiah, R. A'Hern et al., “Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy,” Radiotherapy and Oncology, vol. 99, no. 3, pp. 362–366, 2011.
[11]
A. Andrievski and R. C. Wilkins, “The response of γ-H2AX in human lymphocytes and lymphocytes subsets measured in whole blood cultures,” International Journal of Radiation Biology, vol. 85, no. 4, pp. 369–376, 2009.
[12]
L. A. Beaton, C. Ferrarotto, L. Marro et al., “Chromosome damage and cell proliferation rates in in vitro irradiated whole blood as markers of late radiation toxicity after radiation therapy to the prostate,” International Journal of Radiation Oncology, Biology, Physics, vol. 85, no. 5, pp. 1346–1352, 2013.
[13]
J. D. Cox, J. Stetz, and T. F. Pajak, “Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC),” International Journal of Radiation Oncology, Biology, Physics, vol. 31, no. 5, pp. 1341–1346, 1995.
[14]
S. Chow, D. Hedley, P. Grom, R. Magari, J. W. Jacobberger, and T. V. Shankey, “Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations,” Cytometry Part A, vol. 67, no. 1, pp. 4–17, 2005.
[15]
M. Lew, “Good statistical practice in pharmacology Problem 2,” British Journal of Pharmacology, vol. 152, no. 3, pp. 299–303, 2007.